JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dodelet, V. C.
Right arrow Articles by Pasquale, E. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dodelet, V. C.
Right arrow Articles by Pasquale, E. B.

J Biol Chem, Vol. 274, Issue 45, 31941-31946, November 5, 1999


A Novel Signaling Intermediate, SHEP1, Directly Couples Eph Receptors to R-Ras and Rap1A*

Vincent C. Dodelet, Claudia PazzagliDagger , Andreas H. ZischDagger §, Craig A. Hauser, and Elena B. Pasquale

From the Burnham Institute, La Jolla, California 92037

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Eph family of receptor tyrosine kinases has been implicated in many developmental patterning processes, including cell segregation, cell migration, and axon guidance. The cellular components involved in the signaling pathways of the Eph receptors, however, are incompletely characterized. Using a yeast two-hybrid screen, we have identified a novel signaling intermediate, SHEP1 (SH2 domain-containing Eph receptor-binding protein 1), which is expressed in the embryonic and adult brain. SHEP1 contains an Src homology 2 domain that binds to a conserved tyrosine-phosphorylated motif in the juxtamembrane region of the EphB2 receptor and may itself be a target of EphB2 kinase activity, since it becomes heavily tyrosine-phosphorylated in cells expressing activated EphB2. SHEP1 also contains a domain similar to Ras guanine nucleotide exchange factor domains and binds to the GTPases R-Ras and Rap1A, but not Ha-Ras or RalA. Thus, SHEP1 directly links activated, tyrosine-phosphorylated Eph receptors to small Ras superfamily GTPases.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Eph receptor tyrosine kinases, together with their ephrin ligands, regulate cell segregation, cell migration, and axon guidance and sprouting in the developing embryo, but unlike other families of receptor tyrosine kinases, they have only modest effects on cell proliferation (1-4). Activation of Eph receptors by their cognate ligands leads to cell repulsion in Eph receptor-expressing non-neuronal cells (5) and to growth cone collapse in receptor-expressing neurons (6-8). Changes in cell adhesion to various substrates have also been documented following Eph receptor activation (9, 10).1

Nearly all of the effectors known to interact with activated Eph receptors are well characterized signaling proteins that contain SH2 domains. They include cytoplasmic tyrosine kinases of the Src family (11, 12); the adaptors Grb2, Grb10 (13), and Nck (14); the Ras GTPase-activating protein (15); and the p85 subunit of phosphatidylinositol 3-kinase (16). The Src-like adaptor protein is the only novel protein identified because of its interaction with the cytoplasmic domain of an Eph receptor (17). Src-like adaptor protein consists of an Src homology 2 (SH2)2 and an SH3 domain but does not have a catalytic domain, and its function is unknown.

To further characterize the signaling pathways activated downstream of Eph receptors, we have searched for proteins that interact with autophosphorylated sequence motifs of Eph receptors. We employed the yeast two-hybrid system to screen a mouse embryo cDNA library using the phosphorylated cytoplasmic domain of EphB2 (18) as the bait (12, 19). Two of the isolated clones encoded a protein fragment that was distantly related to the SH2 domains of known proteins. Using expressed sequence tag (EST) data bases and RT-PCR, we obtained a full-length sequence for this novel protein, which we have designated SHEP1 (for SH2 domain-containing Eph receptor-binding protein 1). The structural features of SHEP1 suggest that this protein may be an important signaling intermediate downstream of the Eph receptors.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cloning of SHEP1 cDNA-- Screening of the GenBankTM EST data base using the BLAST algorithm with the partial SHEP1 sequence isolated from the two-hybrid screen retrieved partially overlapping clones containing additional sequences. Further rounds of EST data base searches and reverse transcription polymerase chain reaction amplifications of several murine tissues with the sense primer AGCGGCCGCCCTGGTACCATGGACGCATC (containing a NotI site, underlined) and the antisense primer GAGGACCTTGTCGAACTTCT yielded the entire coding sequence of SHEP1.

Yeast Two-hybrid Assay-- The L40 yeast strain was co-transformed with LexA-EphB2 cytoplasmic domain constructs (12) and a VP16-SHEP1 SH2 domain construct. Co-transformants were first selected on uracil, leucine, tryptophan-deficient medium and replated to test for interaction by growth assay on histidine-deficient medium.

Cell Culture and Transfection-- The 293T human embryonal kidney cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 50 units/ml penicillin, and 50 µg/ml streptomycin at 37 °C. Superfect (Qiagen)-mediated transfections were carried out in accordance with the manufacturer's instructions. Cells were harvested 24-48 h post-transfection.

Preparation of Antibodies-- A GST fusion protein of the SHEP1 SH2 domain (aa 167-324) was expressed in bacteria and purified on glutathione-agarose for injection into rabbits. The immune serum was affinity-purified on a GST-SHEP1 SH2 domain column and then absorbed on a GST-ShcB SH2 domain column to eliminate cross-reacting antibodies. A fusion protein of the extracellular region of the EphB2 receptor and the Fc portion of human IgG1 heavy chain (20) was used as the antigen to produce anti-EphB2 antibodies and for affinity purification. The anti-EphB2 antibodies were absorbed on a human Fc column (Cappel).

Immunoprecipitation and Western Blot Analysis-- Transiently transfected 293T cells and adult mouse spleen were lysed in radioimmune precipitation buffer supplemented with protease inhibitors and sodium orthovanadate. Extracts were precleared for 1 h at 4 °C with protein G-Sepharose (for immunoprecipitation with monoclonal antibodies) or with staphylococcus A (for immunoprecipitation with polyclonal antibodies) and then immunoprecipitated with anti-Myc 9E10 monoclonal antibody bound to protein G-Sepharose or anti-EphB2 or anti-SHEP1 polyclonal antibodies bound to staphylococcus A. Immunoprecipitates were separated by SDS-PAGE, transferred to PVDF membranes (Millipore Corp.), and probed with peroxidase-conjugated PY20 anti-phosphotyrosine antibody (Transduction Laboratories), anti-Myc 9E10 antibody followed by a peroxidase-conjugated goat anti-mouse antibody, or polyclonal antibodies followed by peroxidase-conjugated protein A. Detection was with an enhanced chemiluminescence system (Amersham Pharmacia Biotech).

GST Fusion Protein Binding Assays-- GST fusion proteins of the SHEP1 SH2 domain (aa 167-324), the SHEP1 guanine nucleotide exchange factor (GEF) domain (aa 474-854), or GST alone were expressed in bacteria and purified on glutathione-agarose beads. Transiently transfected 293T cells were lysed in Brij 96 buffer (1% Brij 96, 20 mM Tris-Cl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 2 mM sodium orthovanadate, and protease inhibitor mixture) for the SH2 domain binding assay or lysed in radioimmune precipitation buffer (1% Brij 96 replaced with 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS) for the GEF domain binding assay. Cell extracts were precleared with GST for 30 min at 4 °C followed by incubation with the appropriate GST fusion protein for 1 h at 4 °C. Proteins that bound to the beads were subjected to SDS-PAGE and transferred to polyvinylidene difluoride membrane followed by immunoblotting with anti-EphB2 and EphA4 polyclonal (21) antibodies, anti-Flag polyclonal antibody (Zymed Laboratories Inc.), or the anti-Myc 9E10 monoclonal antibody.

GTPase Exchange Assay-- This assay was performed essentially as described (22). Briefly, purified GST-GTPase fusion proteins were incubated for 30 min at RT with 3H-labeled GDP in exchange buffer (50 mM Tris-Cl, pH 7.5, 50 mM NaCl, 5 mM EDTA, 1 mM dithiothreitol, 1 mg/ml bovine serum albumin). Reactions were then quenched with stop exchange buffer (50 mM Tris-Cl pH 7.5, 10 mM MgCl2, 1 mM dithiothreitol) and diluted with reaction stop buffer (50 mM Tris-Cl, pH 7.5, 2 mM MgCl2, 0.1 mM GTPgamma S). Purified GST fusion proteins of the GEF domains of SHEP1, yeast CDC25, or GST as a control were added to aliquots of the GDP-loaded proteins. The reactions were stopped at the times indicated by filtration through a nitrocellulose filter (Millipore) and washing with stop buffer (50 mM Tris-Cl, pH 7.5, 10 mM MgCl2). Filters were air-dried, and the amount of radioactivity was determined in a scintillation counter.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

cDNA Cloning of SHEP1-- The cytoplasmic domain of the EphB2 receptor tyrosine kinase expressed as a LexA fusion protein was used to screen a VP16 mouse embryo library. The kinase domain of EphB2 is highly active in yeast, resulting in tyrosine autophosphorylation on several residues (12). Accordingly, a large proportion of the clones isolated from the screen encoded the SH2 domains of known signaling molecules. Two identical clones corresponding to a partial sequence of a novel SH2 domain were also isolated (schematically shown in Fig. 1B). We designated the novel protein SHEP1.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 1.   Sequence and domain structure of SHEP1. A, amino acid sequence of SHEP1. The SH2 domain is marked by a dotted underline. The regions corresponding to the three structurally conserved regions (SCR1, SCR2, and SCR3) found in GEF domains are highlighted. Tyrosines outside the SH2 and GEF domains are indicated by a line above; if phosphorylated these tyrosines may represent binding sites for SH2 domains. PXXP sequences, which represent putative binding sites for SH3 domains, are underlined. B, schematic diagram of the domain structure of SHEP1. The SH2 domain, proline/serine-rich region (P/S), and GEF domain are indicated. Bars indicate the sequence obtained from two identical cDNA fragments in the VP16 yeast two-hybrid vector (VP16); mouse EST sequences from GenBankTM (accession numbers are indicated on the right); and the sequence of a SHEP1 RT-PCR fragment (RT-PCR).

Screening of EST data bases with the novel SHEP1 sequence revealed a number of mouse (Fig. 1B) and human (not shown) SHEP1 sequences as well as sequences corresponding to a second closely related protein, which we designated SHEP2 (not shown). The SHEP1 cDNA encodes an 854-amino acid protein (Fig. 1A). A stop codon in frame with the initial methionine is present in the 5'-untranslated sequence (not shown), indicating that the entire coding sequence was identified. A phylogenetic tree (Fig. 2A) illustrates the relationship between the SHEP1 SH2 domain and other previously known SH2 domains.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 2.   SHEP1 belongs to a distinct protein family. Phylogenetic trees showing the relationship between the SH2 domain (A) and GEF domain (B) of SHEP1 and the SH2 domains and GEF domains of other proteins, respectively. The letters before the names of the proteins indicate the species as follows. D, Drosophila; h, human; m, mouse; n, nematode; r, rat. The trees were constructed with the program ClustalW and drawn using the program TreeView. The scale is indicated at the bottom left. For proteins that have two SH2 domains, the amino-terminal (N) or carboxyl-terminal (C) SH2 domain is indicated. KIAA0277 is a predicted coding sequence of an unidentified gene expressed in human brain (54). Two C. elegans sequences with a CDC25-like domain were also used for constructing the tree.

The program ProfileScan (23) also indicated the presence of a weak but significant homology between the carboxyl-terminal portion of SHEP1 and CDC25-like Ras GEF domains (24). The SHEP1 sequences corresponding to the three structurally conserved regions (SCRs) characteristic of GEF domains are highlighted in Fig. 1A. Additional sequence similarities are present throughout the GEF domain. The relationship between the GEF domain of SHEP1 and other previously known GEF domains is illustrated in the phylogenetic tree shown in Fig. 2B. The SHEP1 GEF domain is somewhat divergent from those previously identified, as indicated by the longer branch connecting SHEP1 to the tree.

A notable feature of SHEP1 in the region between the SH2 domain and the GEF domain is the high proportion of prolines (13% of the amino acids) and serines (21% of the amino acids) (Fig. 1A). The proline residues form five PXXP motifs, which conform to the consensus sequence of SH3 domain binding sites (25). This proline/serine-rich region also contains many potential sites of phosphorylation by proline-directed kinases, such as mitogen-activated protein kinases (26). Finally, five tyrosines are present in the serine/proline-rich region of SHEP1, and four are in the amino-terminal segment that precedes the SH2 domain (Fig. 1A). If phosphorylated, these tyrosines may create binding sites for SH2 or phosphotyrosine-binding domains (27).

When SHEP1 was identified, its sequence was not closely related to that of any other known protein. While this work was in progress, sequences closely related to SHEP1 were submitted to GenBankTM, which showed that SHEP1 is part of a family of proteins. The SHEP1 family includes HrSH2 (GenBankTM accession number AB010891), a protein of unknown function isolated from the tunicate Halocynthia roretzi, and BCAR3 (breast cancer anti-estrogen resistance gene 3; GenBankTM accession number U92715), a protein isolated based on its ability to confer tamoxifen resistance to estrogen-dependent breast cancer cells (28). BCAR3 is the same protein that we had designated SHEP2.

Expression of SHEP1 in Fetal and Adult Murine Tissues-- The SHEP1 EST clones (Fig. 1B) were obtained from a wide variety of embryonic and adult tissues, and by RT-PCR we found that SHEP1 transcripts are present in adult brain, spleen, and thymus as well as embryonic brain (Fig. 3A). Hence, SHEP1 mRNA has widespread expression, suggesting that SHEP1 functions in a number of embryonic and adult tissues. To study the SHEP1 protein, we generated a polyclonal antibody to amino acids 167-324 of SHEP1. With this antibody, we immunoprecipitated a single 130-kDa protein from adult mouse spleen and from 293T cells transfected with full-length SHEP1 cDNA (Fig. 3B). Notably, the apparent size of the SHEP1 protein determined by SDS-PAGE is substantially larger than the size of 94 kDa calculated based on the amino acid sequence, suggesting that the mature protein may be post-translationally modified.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 3.   Expression of SHEP1 in murine tissues. A, samples of cDNA from adult mouse thymus, spleen, brain, and fetal brain were used as templates for PCR amplification with SHEP1-specific primers. The arrow on the right marks the bands corresponding to SHEP1, which were verified by sequencing. B, protein extracts of adult mouse spleen, 293T cells transfected with full-length SHEP1, or untransfected 293T cells were immunoprecipitated with a polyclonal anti-SHEP1 antibody, separated by SDS-PAGE, and probed by immunoblotting with the same anti-SHEP1 antibody.

Association of SHEP1 with Eph Receptors-- To further characterize the binding of SHEP1 to Eph receptors, we incubated an immobilized GST fusion protein of the SH2 domain of SHEP1 with extracts of 293T cells expressing tyrosine-phosphorylated EphB2 or EphA4 (12). Immunoblotting showed that the Eph receptors bind the SH2 domain of SHEP1 (Fig. 4A), suggesting that SHEP1 interacts with full-length Eph receptors belonging to both the A and the B subclass (29). Two-hybrid analysis with LexA-EphB2 fusion proteins showed that the SHEP1 SH2 domain interacts with wild-type, phosphorylated EphB2 but not with a kinase-inactive, unphosphorylated mutant (K662R) (12). Mutation of tyrosine 605 in the juxtamembrane domain of EphB2 to glutamic acid (Y605E) or phenylalanine (Y605F) also abrogated binding. This result indicates that this tyrosine is required for binding of the SHEP1 SH2 domain. Mutation of tyrosine 611 to phenylalanine (Y611F), a mutation that severely impairs kinase activity and autophosphorylation (12), also abrogated binding of the SHEP1 SH2 domain. Binding, however, was preserved when tyrosine 611 was mutated to glutamic acid (Y611E), a mutation that does not impair kinase activity and autophosphorylation.3 This indicates that juxtamembrane tyrosine 611 is not required for binding of the SHEP1 SH2 domain. Finally, no binding of SHEP1 to EphB2 was observed when both tyrosines 605 and 611 were mutated to phenylalanine (Y605F/Y611F) or to glutamic acid (Y605E/Y611E).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 4.   The SH2 domain of SHEP1 mediates interactions with Eph receptors. A, a GST-SHEP1 SH2 domain fusion protein binds to full-length EphB2 and EphA4 from transfected 293T cells. In these cells, EphB2 or EphA4 was phosphorylated on tyrosine (not shown). Proteins that bound to the GST-SHEP1 SH2 domain (aa 167-324) were immunoblotted with antibodies to EphB2 or EphA4. The position of molecular weight markers is indicated on the left. B, binding of the SHEP1 SH2 domain requires a phosphorylated sequence comprising tyrosine 605 in the juxtamembrane domain of EphB2. The interaction of the SH2 domain of SHEP1 (fused to the VP16 transactivation domain) and the cytoplasmic domain of EphB2 (fused to the LexA DNA binding domain) was examined by yeast two-hybrid analysis. Co-transfected yeast cells were analyzed by growth assays on histidine-deficient agar (in which growth indicates a positive interaction).

The association of SHEP1 with EphB2 was further verified by co-immunoprecipitation. EphB2 and a Myc-tagged SHEP1 construct containing the SH2 domain were co-transfected in 293T cells, and cell extracts were immunoprecipitated with either anti-Myc antibodies or anti-EphB2 antibodies. Probing by immunoblotting with anti-phosphotyrosine antibodies revealed the presence of EphB2 in the SHEP1 immunoprecipitates (Fig. 5). Conversely, tyrosine-phosphorylated SHEP1 was detected in the EphB2 immunoprecipitates. Probing with anti-Myc antibodies revealed that SHEP1 expressed in the absence of EphB2 had a lower apparent molecular weight than SHEP1 co-expressed with EphB2. These results suggest that EphB2 causes SHEP1 phosphorylation, probably on multiple residues.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 5.   SHEP1 co-precipitates with EphB2 and is tyrosine-phosphorylated in cells expressing activated EphB2. An expression construct of SHEP1 (aa 215-854), tagged at the N terminus with the Myc epitope, was transfected into 293 cells with or without EphB2. Cell lysates were immunoprecipitated with anti-Myc or anti-EphB2 antibodies, and the immunoprecipitates were separated by SDS-PAGE and probed by immunoblotting with anti-phosphotyrosine (anti-PTyr) and anti-Myc 9E10 monoclonal antibodies, respectively.

Association of SHEP1 with Ras Family GTPases-- The presence of both an SH2 and a GEF domain in SHEP1 suggests a novel signaling pathway linked to small Ras superfamily GTPases. GEF domains typically bind and activate small GTPases closely related to Ras (24, 30). Because other results have revealed a connection between EphB2 and R-Ras,1 we hypothesized that SHEP1 may bind R-Ras and serve as a guanine nucleotide exchange factor for this GTPase. R-Ras is a member of the Ras family that has been shown to regulate integrin-mediated cell-matrix adhesion downstream of EphB2 (31).1 No exchange factor specific for R-Ras has been reported (32, 33). To determine whether SHEP1 binds to R-Ras, we incubated a GST fusion protein containing the GEF domain of SHEP1 with extracts of cells transfected with FLAG-tagged constructs of the small Ras family GTPases Ha-Ras, R-Ras, RalA, and Rap1A. Probing the bound proteins with anti-Flag antibodies revealed the presence of substantial levels of R-Ras and Rap1A associated with GST-SHEP1 (Fig. 6A). Proteins containing CDC25-like GEF domains have been shown to have highest affinity for the nucleotide-free state of the GTPases. The SHEP1 GEF domain also exhibited this preference, since wild type R-Ras bound to a much greater extent than the constitutively active, GTP-bound R-Ras38V mutant (Fig. 6B).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 6.   The GEF domain of SHEP1 exhibits specificity for R-Ras and Rap1A. A, a GST-SHEP1 fusion protein containing the GEF domain binds preferentially to the FLAG-tagged GTPases R-Ras and Rap1A. Extracts of 293T cells transfected with FLAG-tagged GTPase constructs or untransfected 293T cells as a control were incubated in radioimmune precipitation buffer with GST-SHEP1 (aa 474-854) bound to glutathione-agarose beads. Bound GTPase proteins were detected by immunoblotting with a polyclonal anti-Flag antibody. Equal amounts of lysates from the transfected cells were also probed with anti-Flag antibodies to show the expression levels of the different GTPases. B, a GST-SHEP1 protein containing the GEF domain binds wild type R-Ras from transfected 293T cells and, to a much lesser extent, constitutively active, GTP-bound, R-Ras38V. Extracts of 293T cells transfected with Myc-tagged wild type R-Ras or R-Ras38V were incubated in 1% Triton X-100 buffer with GST-SHEP1 (aa 474-854) or GST bound to glutathione beads. The samples were washed, and the material remaining associated with the beads and the extracts of the transfected cells were separated by SDS-PAGE and probed with anti-Myc antibodies. C, a GST-SHEP1 protein containing the GEF domain (aa 474-854) does not promote in vitro GDP/GTP exchange. The results are expressed as counts of 3H-labeled GDP remaining bound to GST-R-Ras and GST-Ha-Ras divided by the average counts remaining bound when GST was added instead of an exchange factor. For the 2-h time point, to reveal the weak activation of R-Ras exchange activity induced by the CDC25 GEF domain, the ratios of GST-CDC25 and GST-SHEP1 to GST-R-Ras were 2-fold higher than used for the 1-h time point. Each value is the average of three independent measurements (except for the 2-h time point with GST-CDC25, in which two independent measurements were made). Experimental points are indicated by filled squares.

Guanine nucleotide exchange factors catalyze the release of GDP from Ras family GTPases, and the GDP is then replaced by GTP, which is abundant in the cytoplasm (24). In in vitro exchange assays, the GST fusion protein containing the GEF domain of SHEP1 did not detectably promote the release of 3H-labeled GDP from GST fusions of Ha-Ras and R-Ras (Fig. 6C). As shown before (32), GST-CDC25 efficiently promoted 3H-labeled GDP release from Ha-Ras. GST-CDC25 also promoted a slow release of the labeled nucleotide from R-Ras, showing that the GST-R-Ras fusion protein was competent to bind and release GDP. Exchange assays using RalA and Rap1A yielded results similar to those obtained with R-Ras (not shown). Therefore, the GEF domain of SHEP1 binds R-Ras and Rap1A without promoting GDP/GTP exchange, at least under the conditions of our in vitro experiments.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We report here the isolation of a novel protein, designated SHEP1, that contains an SH2 domain in its N-terminal region, a proline/serine-rich central region, and a C-terminal guanine nucleotide exchange factor domain. SHEP1 associates with Eph receptors via its SH2 domain in a phosphorylation-dependent manner. Co-expression of activated EphB2 receptor and SHEP1 results in tyrosine phosphorylation of the latter, although it is not known if SHEP1 is a direct or indirect target of EphB2. The C-terminal portion of SHEP1, which contains the GEF domain, preferentially binds to the small Ras family GTPases R-Ras and Rap1A, although no exchange activity was observed.

Proteins containing SH2 domains and proteins containing GEF domains are two major classes of proteins that regulate normal cellular signals and can transform cells (34). However, typically SH2 and GEF domains do not occur in the same polypeptide (24, 25, 30). The only exception, in addition to SHEP family proteins, are the proto-oncogenes Vav and Vav2, which are related to each other (35). However, the role of Vav in signaling is likely to be distinct from that of SHEP1. The SH2 domain of Vav, which is located in the carboxyl-terminal part of the protein, is only distantly related to that of SHEP1 (Fig. 2A). The GEF domain of Vav is a Dbl homology domain rather than a CDC25-like domain. In addition, Vav contains an array of other protein and lipid interaction domains (35). Nevertheless, the characterization of Vav as being required in early embryogenesis (36, 37), for lymphocyte development and activation (38, 39), and for integrin signaling in hematopoietic cells (40) has confirmed the expectation that proteins containing both SH2 and GEF domains should have a crucial importance in development and cell transformation.

This is further supported by the recent work of van Agthoven et al. (28), who demonstrate that aberrant expression of the BCAR3/SHEP2 protein in breast cancer cells results in a bypass of estrogen dependence for proliferation, thereby inducing resistance to the anti-estrogen drug tamoxifen. BCAR3/SHEP2 may thus stimulate an alternate growth pathway and/or promote cell survival. The high degree of homology (46% amino acid identity) of BCAR3/SHEP2 with SHEP1 suggests that these two proteins may function in similar pathways involving small Ras GTPases.

Although our assays have not shown a GTP exchange activity for the GEF domain of SHEP1, this may be due to a shortcoming in our understanding of the regulation of SHEP1 catalytic activity. It has been demonstrated that many GEF proteins have negatively regulating regions outside the catalytic domain (41-43). In particular, both Vav and the Rap1A exchange factor, C3G, are activated by phosphorylation of specific tyrosine residues outside the catalytic region (44, 45). Since SHEP1 contains many potential target tyrosines and is heavily phosphorylated when co-expressed with activated EphB2, such a regulatory mechanism may control the GTP exchange activity of SHEP1 in vivo.

It is also possible that R-Ras and Rap1A, although readily bound by SHEP1, are not its physiological targets. Recent studies of GTPase·GEF complexes have highlighted the structural motifs essential for catalytic activity (46-48). Most GEF proteins contain a stabilizing SCR0/Ras effector motif region that seems to be absent in SHEP1. The co-crystal of SOS/Ras has shown that a protruding helical hairpin formed in part by the SCR3 region (see Fig. 1A) plays an important role in the nucleotide exchange mechanism (46). The SHEP1 GEF domain is divergent from other GEF proteins in this region, perhaps indicating that either the mechanism of action of SHEP1 is different or that the target may not be a "classical" Ras protein.

Alternatively, the ability of SHEP1 to bind R-Ras and Rap1A without activating them suggests the intriguing possibility that SHEP1 is not a functional GEF but rather a competitive inhibitor of nucleotide exchange. Finally, SHEP1 may serve as an adaptor, controlling the subcellular localization of certain Ras family GTPases. In the absence of an activated Eph receptor, the PXXP motifs of SHEP1 may interact with SH3 domains in other proteins. For example, SHEP1 may localize R-Ras to focal contacts, where this small GTPase may maintain integrin activation (31), and at other intracellular locations where R-Ras regulates apoptotic signaling pathways (49). Following Eph receptor activation, SHEP1 would become associated with Eph receptors through its SH2 domain. Once associated with Eph receptors, SHEP1 and R-Ras would become tyrosine-phosphorylated. Recent work by Zou et al.1 has indeed shown that EphB2 can mediate tyrosine phosphorylation of R-Ras, which suppresses integrin-mediated cell adhesion. It is unknown whether Rap1A can also be phosphorylated on tyrosine and if such phosphorylation would have similarly negative regulating effects.

During the preparation of this manuscript, the partial sequence of human SHEP1 was published as NSP3 (GenBankTM accession number AF124251). Although no functional data were presented for this protein, a new relative, termed NSP1 (GenBankTM accession number AF124249) (36% amino acid identity with SHEP1), was found to be associated with tyrosine kinase receptors of the epidermal growth factor and insulin receptor families (50). A connection with integrin-mediated adhesion has also been proposed for NSP1, because of its regulated association with p130cas, a docking protein that has been implicated in integrin signaling (51-53). Overexpression of NSP1 in 293 cells also induced the activation of the c-Jun N-terminal kinase 1 and consequently increased the activity of an AP-1-containing promoter. These data are further indication that SHEP1 and the other members of this novel protein family may be important signal transduction intermediates downstream of Eph receptors and other receptor tyrosine kinases in processes such as cell adhesion, cell survival, and embryonic development.

    ACKNOWLEDGEMENTS

We thank Lawrence Quilliam for the GST-Ha-Ras, GST-CDC25, and FLAG-tagged GTPase plasmids and for helpful advice; Andrew Freeman for the preparation of anti-SHEP1 antibodies; June Zou for the GST-R-Ras plasmid; and Erkki Ruoslahti for helpful comments on the manuscript.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants HD25938 and HD26351 (to E. B. P.) and by a postdoctoral fellowship from the National Sciences and Engineering Research Council of Canada (to V. C. D.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF168364.

Dagger These authors contributed equally to the work.

§ Present address: Dept. of Materials and Inst. for Biomedical Engineering, ETH Zurich and the University of Zurich, CH-8044 Switzerland.

To whom correspondence should be addressed: The Burnham Institute, 10901 N. Torrey Pines Rd., La Jolla CA 92037. Tel.: 619-646-3131; Fax: 619-646-3199; elenap{at}ljcrf.edu.

1 Zou, J. X., Wang, B., Kalo, M. S., Zisch, A. H., Pasquale, E. B., and Ruoslahti, E. Proc. Natl. Acad. Sci. U. S. A., in press.

3 Zisch, A. H., Pazzagli, C., Freeman, A. L., Schneller, M., Hadman, M., Smith, J. W., Ruoslahti, E., and Pasquale, E. B., Oncogene, in press.

    ABBREVIATIONS

The abbreviations used are: SH2, Src homology 2; SH3, Src homology 3; EST, expressed sequence tag; PCR, polymerase chain reaction; RT-PCR, reverse transcription PCR; PAGE, polyacrylamide gel electrophoresis; GST, glutathione S-transferase; aa, amino acids; GEF, guanine nucleotide exchange factor; GTPgamma S, guanosine 5'-O-(thiotriphosphate); SCR, structurally conserved region.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Drescher, U. (1997) Curr. Biol. 7, R799-R807[CrossRef][Medline] [Order article via Infotrieve]
2. Pasquale, E. B. (1997) Curr. Opin. Cell Biol. 9, 608-615[CrossRef][Medline] [Order article via Infotrieve]
3. Bruckner, K., and Klein, R. (1998) Curr. Opin. Neurobiol. 8, 375-382[CrossRef][Medline] [Order article via Infotrieve]
4. Flanagan, J. G., and Vanderhaeghen, P. (1998) Annu. Rev. Neurosci. 21, 309-345[CrossRef][Medline] [Order article via Infotrieve]
5. Wang, H. U., and Anderson, D. J. (1997) Neuron 18, 383-396[CrossRef][Medline] [Order article via Infotrieve]
6. Drescher, U., Kremoser, C., Handwerker, C., Loschinger, J., Noda, M., and Bonhoeffer, F. (1995) Cell 82, 359-370[CrossRef][Medline] [Order article via Infotrieve]
7. Meima, L., Moran, P., Matthews, W., and Caras, I. W. (1997) Mol. Cell. Neurosci. 9, 314-328[CrossRef][Medline] [Order article via Infotrieve]
8. Meima, L., Kljavin, I. J., Moran, P., Shih, A., Winslow, J. W., and Caras, I. W. (1997) Eur. J. Neurosci. 9, 177-188[CrossRef][Medline] [Order article via Infotrieve]
9. Stein, E., Lane, A. A., Cerretti, D. P., Schoecklmann, H. O., Schroff, A. D., Van Etten, R. L., and Daniel, T. O. (1998) Genes Dev. 12, 667-678[Abstract/Free Full Text]
10. Huynh-Do, U., Stein, E., Lane, A. A., Liu, H., Cerretti, D. P., and Daniel, T. O. (1999) EMBO J. 18, 2165-2173[CrossRef][Medline] [Order article via Infotrieve]
11. Ellis, C., Kasmi, F., Ganju, P., Walls, E., Panayotou, G., and Reith, A. D. (1996) Oncogene 12, 1727-1736[Medline] [Order article via Infotrieve]
12. Zisch, A. H., Kalo, M. S., Chong, L. D., and Pasquale, E. B. (1998) Oncogene 16, 2657-2670[CrossRef][Medline] [Order article via Infotrieve]
13. Stein, E., Cerretti, D. P., and Daniel, T. O. (1996) J. Biol. Chem. 271, 23588-23593[Abstract/Free Full Text]
14. Stein, E., Huynh-Do, U., Lane, A. A., Cerretti, D. P., and Daniel, T. O. (1998) J. Biol. Chem. 273, 1303-1308[Abstract/Free Full Text]
15. Holland, S. J., Gale, N. W., Gish, G. D., Roth, R. A., Zhou, S. Y., Cantley, L. C., Henkemeyer, M., Yancopoulos, G. D., and Pawson, T. (1997) EMBO J. 16, 3877-3888[CrossRef][Medline] [Order article via Infotrieve]
16. Pandey, A., Lazar, D. F., Saltiel, A. R., and Dixit, V. M. (1994) J. Biol. Chem. 269, 30154-30157[Abstract/Free Full Text]
17. Pandey, A., Duan, H., and Dixit, V. M. (1995) J. Biol. Chem. 270, 19201-19204[Abstract/Free Full Text]
18. Pasquale, E. B. (1991) Cell Regul. 2, 523-534[Medline] [Order article via Infotrieve]
19. Vojtek, A. B., and Hollenberg, S. M. (1995) Methods Enzymol. 255, 331-342[Medline] [Order article via Infotrieve]
20. Shao, H., Lou, L., Pandey, A., Pasquale, E. B., and Dixit, V. M. (1994) J. Biol. Chem. 269, 26606-26609[Abstract/Free Full Text]
21. Soans, C., Holash, J. A., and Pasquale, E. B. (1994) Oncogene 9, 3353-3361[Medline] [Order article via Infotrieve]
22. Debant, A., Serra-Pages, C., Seipel, K., O'Brien, S., Tang, M., and Park, S. H. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5466-5471[Abstract/Free Full Text]
23. Bairoch, A., Bucher, P., and Hofmann, K. (1996) Nucleic Acids Res. 24, 189-196[Abstract/Free Full Text]
24. Boguski, M. S., and McCormick, F. (1993) Nature 366, 643-654[CrossRef][Medline] [Order article via Infotrieve]
25. Cohen, G. B., Ren, R., and Baltimore, D. (1995) Cell 80, 237-248[CrossRef][Medline] [Order article via Infotrieve]
26. Pearson, R. B., and Kemp, B. E. (1991) Methods Enzymol. 200, 62-81[Medline] [Order article via Infotrieve]
27. Pawson, T., and Scott, J. D. (1997) Science 278, 2075-2080[Abstract/Free Full Text]
28. van Agthoven, T., van Agthoven, T. L., Dekker, A., van der Spek, P. J., Vreede, L., and Dorssers, L. C. (1998) EMBO J. 17, 2799-2808[CrossRef][Medline] [Order article via Infotrieve]
29. Flanagan, J. G., Gale, N. W., Hunter, T., Pasquale, E. B., and Tessier-Lavigne, M. (1997) Cell 90, 403-404[CrossRef][Medline] [Order article via Infotrieve]
30. Quilliam, L. A., Khosravi-Far, R., Huff, S. Y., and Der, C. J. (1995) BioEssays 17, 395-404[CrossRef][Medline] [Order article via Infotrieve]
31. Zhang, Z., Vuori, K., Wang, H., Reed, J. C., and Ruoslahti, E. (1996) Cell 85, 61-69[CrossRef][Medline] [Order article via Infotrieve]
32. Gotoh, T., Niino, Y., Tokuda, M., Hatase, O., Nakamura, S., Matsuda, M., and Hattori, S. (1997) J. Biol. Chem. 272, 18602-18607[Abstract/Free Full Text]
33. Huff, S. Y., Quilliam, L. A., Cox, A. D., and Der, C. J. (1997) Oncogene 14, 133-143[CrossRef][Medline] [Order article via Infotrieve]
34. Hunter, T. (1997) Cell 88, 333-346[CrossRef][Medline] [Order article via Infotrieve]
35. Collins, T. L., Deckert, M., and Altman, A. (1997) Immunol. Today 18, 221-225[CrossRef][Medline] [Order article via Infotrieve]
36. Zmuidzinas, A., Fischer, K. D., Lira, S. A., Forrester, L., Bryant, S., Bernstein, A., and Barbacid, M. (1995) EMBO J. 14, 1-11[Medline] [Order article via Infotrieve]
37. Olson, M. F., Pasteris, N. G., Gorski, J. L., and Hall, A. (1996) Curr. Biol. 6, 1628-1633[CrossRef][Medline] [Order article via Infotrieve]
38. Zhang, R., Alt, F. W., Davidson, L., Orkin, S. H., and Swat, W. (1995) Nature 374, 470-473[CrossRef][Medline] [Order article via Infotrieve]
39. Tarakhovsky, A., Turner, M., Schaal, S., Mee, P. J., Duddy, L. P., Rajewsky, K., and Tybulewicz, V. L. (1995) Nature 374, 467-470[CrossRef][Medline] [Order article via Infotrieve]
40. Miranti, C. K., Leng, L., Maschberger, P., Brugge, J. S., and Shattil, S. J. (1998) Curr. Biol. 8, 1289-1299[CrossRef][Medline] [Order article via Infotrieve]
41. Baouz, S., Jacquet, E., Bernardi, A., and Parmeggiani, A. (1997) J. Biol. Chem. 272, 6671-6676[Abstract/Free Full Text]
42. Corbalan-Garcia, S., Margarit, S. M., Galron, D., Yang, S. S., and Bar-Sagi, D. (1998) Mol. Cell. Biol. 18, 880-886[Abstract/Free Full Text]
43. Qian, X., Vass, W. C., Papageorge, A. G., Anborgh, P. H., and Lowy, D. R. (1998) Mol. Cell. Biol. 18, 771-778[Abstract/Free Full Text]
44. Crespo, P., Schuebel, K. E., Ostrom, A. A., Gutkind, J. S., and Bustelo, X. R. (1997) Nature 385, 169-172[CrossRef][Medline] [Order article via Infotrieve]
45. Ichiba, T., Hashimoto, Y., Nakaya, M., Kuraishi, Y., Tanaka, S., Kurata, T., Mochizuki, N., and Matsuda, M. (1999) J. Biol. Chem. 274, 14376-14381[Abstract/Free Full Text]
46. Boriack-Sjodin, P. A., Margarit, S. M., Bar-Sagi, D., and Kuriyan, J. (1998) Nature 394, 337-343[CrossRef][Medline] [Order article via Infotrieve]
47. Cherfils, J., Menetrey, J., Mathieu, M., Le Bras, G., Robineau, S., Beraud-Dufour, S., Antonny, B., and Chardin, P. (1998) Nature 392, 101-105[CrossRef][Medline] [Order article via Infotrieve]
48. Mossessova, E., Gulbis, J. M., and Goldberg, J. (1998) Cell 92, 415-423[CrossRef][Medline] [Order article via Infotrieve]
49. Wang, H. G., Millan, J. A., Cox, A. D., Der, C. J., Rapp, U. R., Beck, T., Zha, H., and Reed, J. C. (1995) J. Cell Biol. 129, 1103-1114[Abstract/Free Full Text]
50. Lu, Y., Brush, J., and Stewart, T. A. (1999) J. Biol. Chem. 274, 10047-10052[Abstract/Free Full Text]
51. Harte, M. T., Hildebrand, J. D., Burnham, M. R., Bouton, A. H., and Parsons, J. T. (1996) J. Biol. Chem. 271, 13649-13655[Abstract/Free Full Text]
52. Cary, L. A., Han, D. C., Polte, T. R., Hanks, S. K., and Guan, J. L. (1998) J. Cell Biol. 140, 211-221[Abstract/Free Full Text]
53. Garcia-Guzman, M., Dolfi, F., Russello, M., and Vuori, K. (1999) J. Biol. Chem. 274, 5762-5768[Abstract/Free Full Text]
54. Nagase, T., Seki, N., Ishikawa, K., Ohira, M., Kawarabayasi, Y., Ohara, O., Tanaka, A., Kotani, H., Miyajima, N., and Nomura, N. (1996) DNA Res. 3, 321-329[Abstract], 341-354


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. L. De Jesus, M. B. Stope, P. A. O. Weernink, Y. Mahlke, C. Borgermann, V. N. Ananaba, C. Rimmbach, D. Rosskopf, M. C. Michel, K. H. Jakobs, et al.
Cyclic AMP-dependent and Epac-mediated Activation of R-Ras by G Protein-coupled Receptors Leads to Phospholipase D Stimulation
J. Biol. Chem., August 4, 2006; 281(31): 21837 - 21847.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
M. Dail, M. Richter, P. Godement, and E. B. Pasquale
Eph receptors inactivate R-Ras through different mechanisms to achieve cell repulsion
J. Cell Sci., April 1, 2006; 119(7): 1244 - 1254.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Briknarova, F. Nasertorabi, M. L. Havert, E. Eggleston, D. W. Hoyt, C. Li, A. J. Olson, K. Vuori, and K. R. Ely
The Serine-rich Domain from Crk-associated Substrate (p130cas) Is a Four-helix Bundle
J. Biol. Chem., June 10, 2005; 280(23): 21908 - 21914.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
K. N. Felekkis, R. P. Narsimhan, R. Near, A. F. Castro, Y. Zheng, L. A. Quilliam, and A. Lerner
AND-34 Activates Phosphatidylinositol 3-Kinase and Induces Anti-Estrogen Resistance in a SH2 and GDP Exchange Factor-Like Domain-Dependent Manner
Mol. Cancer Res., January 1, 2005; 3(1): 32 - 41.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Dail, M. S. Kalo, J. A. Seddon, J.-F. Cote, K. Vuori, and E. B. Pasquale
SHEP1 Function in Cell Migration Is Impaired by a Single Amino Acid Mutation That Disrupts Association with the Scaffolding Protein Cas but Not with Ras GTPases
J. Biol. Chem., October 1, 2004; 279(40): 41892 - 41902.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
E. K. Park, N. Warner, Y.-S. Bong, D. Stapleton, R. Maeda, T. Pawson, and I. O. Daar
Ectopic EphA4 Receptor Induces Posterior Protrusions via FGF Signaling in Xenopus Embryos
Mol. Biol. Cell, April 1, 2004; 15(4): 1647 - 1655.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Biol.Home page
C. Vindis, D. P. Cerretti, T. O. Daniel, and U. Huynh-Do
EphB1 recruits c-Src and p52Shc to activate MAPK/ERK and promote chemotaxis
J. Cell Biol., August 18, 2003; 162(4): 661 - 671.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
K. K. Murai and E. B. Pasquale
`Eph'ective signaling: forward, reverse and crosstalk
J. Cell Sci., July 15, 2003; 116(14): 2823 - 2832.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
A. Sakakibara, Y. Ohba, K. Kurokawa, M. Matsuda, and S. Hattori
Novel function of Chat in controlling cell adhesion via Cas-Crk-C3G-pathway-mediated Rap1 activation
J. Cell Sci., March 14, 2003; 115(24): 4915 - 4924.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Freywald, N. Sharfe, C. Rashotte, T. Grunberger, and C. M. Roifman
The EphB6 Receptor Inhibits JNK Activation in T Lymphocytes and Modulates T Cell Receptor-mediated Responses
J. Biol. Chem., March 14, 2003; 278(12): 10150 - 10156.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Sakakibara, S. Hattori, S. Nakamura, and T. Katagiri
A Novel Hematopoietic Adaptor Protein, Chat-H, Positively Regulates T Cell Receptor-mediated Interleukin-2 Production by Jurkat Cells
J. Biol. Chem., February 14, 2003; 278(8): 6012 - 6017.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Cai, K. N. Felekkis, R. I. Near, G. M. O'Neill, J. M. van Seventer, E. A. Golemis, and A. Lerner
The GDP Exchange Factor AND-34 Is Expressed in B Cells, Associates With HEF1, and Activates Cdc42
J. Immunol., January 15, 2003; 170(2): 969 - 978.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
K.-I. Nagashima, A. Endo, H. Ogita, A. Kawana, A. Yamagishi, A. Kitabatake, M. Matsuda, and N. Mochizuki
Adaptor Protein Crk Is Required for Ephrin-B1-induced Membrane Ruffling and Focal Complex Assembly of Human Aortic Endothelial Cells
Mol. Biol. Cell, December 1, 2002; 13(12): 4231 - 4242.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
N. Prevost, D. Woulfe, T. Tanaka, and L. F. Brass
Interactions between Eph kinases and ephrins provide a mechanism to support platelet aggregation once cell-to-cell contact has occurred
PNAS, July 9, 2002; 99(14): 9219 - 9224.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
I. D. Lawrenson, S. H. Wimmer-Kleikamp, P. Lock, S. M. Schoenwaelder, M. Down, A. W. Boyd, P. F. Alewood, and M. Lackmann
Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3-expressing 293T and melanoma cells by CrkII and Rho-mediated signalling
J. Cell Sci., January 3, 2002; 115(5): 1059 - 1072.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
S. J. Fashena, M. B. Einarson, G. M. O'Neill, C. Patriotis, and E. A. Golemis
Dissection of HEF1-dependent functions in motility and transcriptional regulation
J. Cell Sci., January 1, 2002; 115(1): 99 - 111.
[Abstract] [Full Text] [PDF]